Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer

drugsApril 17, 2019

Tag: Balversa , Erdafitinib , FDA , FGFR , cancer

PharmaSources Customer Service